These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 34156057)

  • 1. Redirecting natural killer cells to potentiate adoptive immunotherapy in solid tumors through stabilized Y-type bispecific aptamer.
    Zheng Y; Zhang C; Lai Z; Zeng Y; Li J; Zhang D; Liu X
    Nanoscale; 2021 Jul; 13(25):11279-11288. PubMed ID: 34156057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Equipping Natural Killer Cells with Specific Targeting and Checkpoint Blocking Aptamers for Enhanced Adoptive Immunotherapy in Solid Tumors.
    Zhang D; Zheng Y; Lin Z; Liu X; Li J; Yang H; Tan W
    Angew Chem Int Ed Engl; 2020 Jul; 59(29):12022-12028. PubMed ID: 32246555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Artificial Engineered Natural Killer Cells Combined with Antiheat Endurance as a Powerful Strategy for Enhancing Photothermal-Immunotherapy Efficiency of Solid Tumors.
    Zhang D; Zheng Y; Lin Z; Lan S; Zhang X; Zheng A; Li J; Liu G; Yang H; Liu X; Liu J
    Small; 2019 Oct; 15(42):e1902636. PubMed ID: 31468667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes.
    Liu J; Yang S; Cao B; Zhou G; Zhang F; Wang Y; Wang R; Zhu L; Meng Y; Hu C; Liang H; Lin X; Zhu K; Chen G; Luo KQ; Di L; Zhao Q
    J Hematol Oncol; 2021 Jan; 14(1):21. PubMed ID: 33514401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TLS11a Aptamer/CD3 Antibody Anti-Tumor System for Liver Cancer.
    Hu Z; He J; Gong W; Zhou N; Zhou S; Lai Z; Zheng R; Wang Y; Yang X; Yang W; Zhong L; Lu X; Zhao Y
    J Biomed Nanotechnol; 2018 Sep; 14(9):1645-1653. PubMed ID: 29958558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.
    Shi L; Lin H; Li G; Sun Y; Shen J; Xu J; Lin C; Yeh S; Cai X; Chang C
    Cancer Lett; 2016 Apr; 373(1):45-56. PubMed ID: 26805759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy.
    Ohira M; Ohdan H; Mitsuta H; Ishiyama K; Tanaka Y; Igarashi Y; Asahara T
    Transplantation; 2006 Dec; 82(12):1712-9. PubMed ID: 17198265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
    Jiang W; Zhang C; Tian Z; Zhang J
    Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expansion and activation of natural killer cells from PBMC for immunotherapy of hepatocellular carcinoma.
    Peng BG; Liang LJ; He Q; Huang JF; Lu MD
    World J Gastroenterol; 2004 Jul; 10(14):2119-23. PubMed ID: 15237448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tribody [(HER2)
    Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
    Front Immunol; 2018; 9():814. PubMed ID: 29725336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
    Kamiya T; Chang YH; Campana D
    Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Bispecific Aptamer Enhances Immune Cytotoxicity Against MUC1-Positive Tumor Cells by MUC1-CD16 Dual Targeting.
    Li Z; Hu Y; An Y; Duan J; Li X; Yang XD
    Molecules; 2019 Jan; 24(3):. PubMed ID: 30699986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suicide gene-modified killer cells as an allogeneic alternative to autologous cytokine-induced killer cell immunotherapy of hepatocellular carcinoma.
    Wu T; Leboeuf C; Durand S; Su B; Deschamps M; Zhang X; Ferrand C; Pessaux P; Robinet E
    Mol Med Rep; 2016 Mar; 13(3):2645-54. PubMed ID: 26820174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel bispecific antibody, BiSS, with potent anti-cancer activities.
    Dong B; Zhou C; He P; Li J; Chen S; Miao J; Li Q; Wang Z
    Cancer Biol Ther; 2016 Apr; 17(4):364-70. PubMed ID: 26828900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma.
    Rothe A; Jachimowicz RD; Borchmann S; Madlener M; Keßler J; Reiners KS; Sauer M; Hansen HP; Ullrich RT; Chatterjee S; Borchmann P; Yazaki P; Koslowsky TC; Engert A; Heukamp LC; Hallek M; von Strandmann EP
    Int J Cancer; 2014 Jun; 134(12):2829-40. PubMed ID: 24242212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI-guided interventional natural killer cell delivery for liver tumor treatment.
    Su Z; Wang X; Zheng L; Lyu T; Figini M; Wang B; Procissi D; Shangguan J; Sun C; Pan L; Qin L; Zhang B; Velichko Y; Salem R; Yaghmai V; Larson AC; Zhang Z
    Cancer Med; 2018 May; 7(5):1860-1869. PubMed ID: 29601672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma.
    Yu M; Luo H; Fan M; Wu X; Shi B; Di S; Liu Y; Pan Z; Jiang H; Li Z
    Mol Ther; 2018 Feb; 26(2):366-378. PubMed ID: 29339014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanobody-Engineered Natural Killer Cell Conjugates for Solid Tumor Adoptive Immunotherapy.
    Gong L; Li Y; Cui K; Chen Y; Hong H; Li J; Li D; Yin Y; Wu Z; Huang Z
    Small; 2021 Nov; 17(45):e2103463. PubMed ID: 34761524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
    Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
    Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer.
    Del Bano J; Florès-Florès R; Josselin E; Goubard A; Ganier L; Castellano R; Chames P; Baty D; Kerfelec B
    Front Immunol; 2019; 10():1593. PubMed ID: 31354732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.